Products
Human TCRsafe® analysis
Clinical samples for T-cell receptor repertoire analysis often contain only small amounts of relevant genomic DNA. As a consequence, prior to sequencing massive parallel TCR-template amplification by PCR is necessary, which increases the risk of contamination by foreign DNA. HSDiagnomics uses a sophisticated and unique 2-step PCR approach with inbuilt contamination protection, which efficiently eliminates DNA contaminations both during PCR and/or during sequence analysis.
Employing a synthetic TCRß reference template, all primers (43 V-segment- and 14 J-segment-primers) were carefully calibrated to allow uniform amplification rates for all possible V/J-combinations. Additionally, our TCRsafe® PCR for TCRα amplification has been optimized to ensure accurate quantitative results.
Our TCRsafe® service packages for TCRß and TCRα profiling in cancer and autoimmune diseases also include Formalin-fixed paraffin-embedded (FFPE) tissue analysis. Through overlapping paired-end sequencing, we consistently yield high-quality sequence data. Interested customers are welcome to contact us for more details.
Mouse TCRsafe® analysis
There are strong interests by researchers in academic and industry labs to perform T-cell response analyses under various experimental conditions in mouse model systems.
HSDiagnomics addresses these needs by a proprietary mouse TCRsafe® service package. It comprises a thoroughly optimized quantitative TCRß analysis, which is equipped with the same contamination protection system as the human TCRsafe® kit. Standard fresh samples (DNA, RNA, from blood, tissues) as well as formalin-fixed and paraffin-embedded tissue can be analyzed.
Examples for TCRß analyses in thymi of 5 wildtype (C57Bl/6) mice are given here and the optimization of the quantitative TCRß analysis employing a synthetic reference template has been published here.
TCanceR Database of predicted tumor-specific T-cell receptors (tsTCRs)
HSDiagnomics maintains a large database of TCR sequences from tumor and adjacent healthy tissues as a proven source for therapeutic TCR development and identification of cancer specific antigens (More information is given here). Our database is focused on prevalent solid cancers with high clinical need such as lung cancer (NSCLC), pancreatic cancer (PDAC), and colorectal cancer (CRC) and facilitates precise comparison with TCR repertoires from healthy individuals.
The database comprises paired T-cell receptor data (TCR α and ß chains) obtained from FACS-sorted T-cells (CD3, CD8, PD1), as well as T-cell receptors from micro-dissected FFPE tumor and adjacent non-tumor tissues. Moreover, HLA type and/or single cell expression data are available for the majority of samples.
Our proprietary bioinformatics pipeline is streamlined to quantitatively compare the TCR repertoires of tumor-infiltrating T cells with those in adjacent healthy tissues. Furthermore, it facilitates the identification of tsTCR clusters across patients and tumor entities.
By determining the HLA type of tsTCR clusters, the screening for cancer antigens is facilitated. This allows for employing the tsTCR as a probe and screening of common neo-antigen candidates in tumors to be recognized by the tsTCR.
Our database is not limited to frequent HLA types; it covers the entire HLA spectrum. We believe that considering all HLA types offers new opportunities for antigen discovery and widens the application of TCR-T therapy.
HS Diagnomics GmbH
Schloßstrasse 110
12163 Berlin
Germany
Tel. +49(30)700 14 53 30
Fax +49(30)546 11 698
Customer Support
Tel. +49(30)700 14 53 31
News
06/2024
Project Update: HS Diagnomics has entered into the international collaborative project ELEVATE with TU Wien, NMI Tübingen, Sciospec, UpNano, and THT Biomaterials
Read more ...
10/2023
HSDiagnomics partners with Charité University Medicine Berlin, TheryCell GmbH, and EPO GmbH in an innovative project to advance TCR-T therapy for solid tumors
Read more ...
06/2020
TCRsafe® analysis of a Runx1 knockout mouse model provides evidence for a role of RUNX1 as a recombinase cofactor for TCRß rearrangements and pathological deletions
Read more ...
08/2019
ZIM-Project TCR-specific Antigen Identification - TAgID
Read more ...
04/2018
Patent granted for the identification of tumor-specific T-cell receptors
Read more ...